VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MNPR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MNPRMonopar Therapeutics Inc.
$70.75$474M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksMNPRCash Flow

Monopar Therapeutics Inc. (MNPR) Cash Flow Statement

11Y historyFree accessUpdated daily

Operating cash flow has been negative in most periods, with 2026Q3 operating cash outflow of -$6.2M matching the net loss, and free cash flow remains persistently negative with no dividends and minimal buybacks suggesting capital is retained for trials.

Income StatementBalance SheetCash FlowRatios

MNPR Cash Flow Statement

Annual statement

MNPR Cash Flow Statement

Monopar Therapeutics Inc. (MNPR) cash flow statement — 11-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15
Cash from Operations-3.26B-12.2M-6.4M-7.86M-7.23M-7.32M-4.66M-3.02M-2.89M-2.63M-1.19M-636.33K
Operating CF Margin %------------
Operating CF Growth %-225.34%-90.52%18.5%-8.71%1.21%-56.95%-54.5%-4.54%-9.87%-119.94%-87.74%-
Net Income-20.6M-13.72M-15.59M-8.4M-10.52M-9.1M-6.3M-4.22M-3.23M-16.55M-1.19M-687.31K
Depreciation & Amortization0000006.51M03.33M2.1M1.19M0
Stock-Based Compensation1.43B4.84M1.14M1.9M1.64M1.47M1.32M1.01M529.33K305.2K00
Deferred Taxes000000000000
Other Non-Cash Items848.98M-716.46K4.54M000-6.63M0-3.33M11.4M-1.19M-73.84K
Working Capital Changes-214.14M-2.61M3.5M-1.35M1.65M317.77K443.81K196.02K-188.16K120.58K-9.04K50.98K
Change in Receivables000000000000
Change in Inventory000000000000
Change in Payables1.56B388.22K506.79K-1.33M1.48M403.97K447.6K243.53K87.68K247.36K-9.33K73.84K
Cash from Investing4.05B-63.45M-14.34M4.93M-4.92M0000000
Capital Expenditures000000000000
CapEx % of Revenue------------
Acquisitions000000000000
Investments------------
Other Investing000000000000
Cash from Financing-647.39M91.57M59.29M2.03M32.87K10.88M8.18M9.35M-206.27K9.54M1.26M3.44M
Debt Issued (Net)000000122.4K00000
Equity Issued (Net)8.17M92.71M59.4M2.07M109.34K10.93M8.18M10.22M04.71M1.26M0
Dividends Paid000000000000
Share Repurchases-200.2K-35M0000000000
Other Financing-655.56M-1.13M-104.14K-46.97K-76.46K-45.77K-115.57K-874.81K-206.27K4.83M03.44M
Net Change in Cash138.25M16.02M38.55M-920.11K-12.12M3.57M3.52M6.32M-2.89M6.91M67.87K2.81M
Free Cash Flow-3.26B-12.2M-6.4M-7.86M-7.23M-7.32M-4.66M-3.02M-2.89M-2.63M-1.19M-636.33K
FCF Margin %------------
FCF Growth %-30006.78%-90.52%18.5%-8.71%1.21%-56.95%-54.5%-4.54%-9.87%-119.94%-87.74%-
FCF per Share-380.83-1.65-0.56-0.54-0.57-0.59-0.43-0.29-0.28-0.25-0.12-0.08
FCF Conversion (FCF/Net Income)158.25x0.89x0.41x0.94x0.69x0.80x0.74x0.71x0.89x0.16x1.01x0.93x
Interest Paid000000000000
Taxes Paid000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Ongoing clinical cash burn without revenue

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Net Losses Mirror Operating Cash Burn

Based on reported quarterly figures, MNPR's operating cash flow has been negative in most periods, with 2026Q3 showing operating cash flow of -$6.2M that matches its net loss almost exactly, implying minimal accrual distortion in the reported losses.

Because operating cash flow tracks net income closely in several quarters, reported losses appear to be largely real cash outflows rather than non-cash charges. The OCF/NI ratio near 1.00 in 2026Q3 and 0.89 in 2026Q1 suggests the earnings base is cash-consistent, though the 2026Q2 figure appears anomalous and warrants further investigation before drawing conclusions. Investors should monitor whether this cash-consistent pattern persists as trial spending scales.

Free Cash Flow Remains Persistently Negative

As reported in the quarterly cash flow statements, MNPR's free cash flow has been negative across all ten periods, with the most recent quarter showing -$6.2M, indicating no internal funding capacity from operations.

With capital expenditures effectively zero, free cash flow equals operating cash flow, and the absence of any positive quarter reflects a business with no revenue offset. The magnitude of burn in 2026Q2, which the data flags at an unusually large figure, appears inconsistent with surrounding quarters and may reflect a reporting or classification issue that warrants further investigation. The overall trajectory suggests reliance on external capital to sustain operations.

Cash Directed to Trials, Not Shareholders

Based on reported figures, MNPR paid no dividends in any period and recorded buybacks only in 2026Q1 at -$200.2K, with no acquisition cash flows reported, suggesting capital is being retained for clinical programs.

The absence of dividends and the negligible buyback activity are consistent with a company that must preserve liquidity to fund Validive and Camsirubicin development. The single 2025Q3 outflow near -$35.0M is not clearly explained by the supplied data and should not be read as a sustainable deployment pattern. Shareholders should recognize that any return of capital is unlikely while the company remains pre-revenue.

Working Capital Swings Obscure Burn Rate

According to the reported cash flow data, MNPR's working capital changes swung from -$213.8M in 2026Q2 to +$1.4M in 2025Q4, with figures of this magnitude appearing inconsistent with the company's scale and suggesting data-quality limitations.

Large swings in working capital can distort the apparent operating burn, and the extreme 2026Q2 figure makes the quarterly trend difficult to interpret reliably. Accrued clinical trial expenses, which the company typically carries, may lag actual activity and contribute to these fluctuations. Analysts should rely on cumulative operating burn rather than any single quarter's working capital reading.

Burn Rate Obscured by Data Anomalies

Based on the supplied cash flow series, the most reliable read of MNPR's burn comes from the smaller quarterly outflows, since anomalous 2026Q2 and 2025Q3 entries could materially overstate or understate the true cash consumption rate.

Taken at face value, the extreme values in the reported working capital and operating cash flow lines would imply a very different funding picture than the modest net losses on the income statement, which warrants further investigation rather than acceptance. Stock-based compensation add-backs of up to $2.0M per quarter reduce the reported cash gap without changing the underlying need for external capital. Investors should treat the cumulative burn trend and the cash runway implied by the balance sheet as more decision-useful than any isolated quarter.

MNPR — Frequently Asked Questions

Quick answers to the most common questions about buying MNPR stock.

How much cash does Monopar Therapeutics Inc. (MNPR) generate from operations?

Monopar Therapeutics Inc. (MNPR) generated $-12.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Monopar Therapeutics Inc.'s free cash flow?

Monopar Therapeutics Inc. (MNPR) reported negative free cash flow of $12.2M in 2025, indicating capital requirements exceeded cash from operations.

What is Monopar Therapeutics Inc.'s capital expenditure (CapEx)?

Monopar Therapeutics Inc. (MNPR) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Monopar Therapeutics Inc. distribute cash to shareholders?

In 2025, Monopar Therapeutics Inc. (MNPR) spent $35.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.